Novel treatment regimens for Waldenstr?m's macroglobulinemia

[Guest guest]

BlankNovel treatment regimens for Waldenstr?m's macroglobulinemia.

R -Sanz and EM Ocio

Expert Rev Hematol, June 1, 2010; 3(3): 339-50.

University Hospital of Salamanca, Universidad de Salamanca-Consejo Superior de

Investigaciones Cient?ficas, Paseo de San Vicente 58-182, Salamanca 37007,

Spain.

Waldenstrom's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder

defined by bone marrow infiltration by lymphoplasmacytic cells as defined by the

current classification systems. According to its transition situation between

mutated chronic lymphocytic leukemia and multiple myeloma, several new

therapeutic alternatives have been proposed for this entity based on the

experience with these two well-known conditions together with the highly

singular data provided by preclinical models. Thus, in WM two main therapeutic

attitudes are possible: the use of conventional therapies based on the

administration of single drugs or combinations with alkylating agents, purine

analogues and anti-CD20 monoclonal antibodies; or the use of very new

combinations that, without rejecting the previously mentioned drugs, include new

agents, such as proteasome inhibitors, immunomodulatory agents or even histone

deacetylase inhibitors and PI3K/AKT inhibitors, among others. Here we review the

most recent results reported for the use of new combinations and new drugs in

patients with WM at different stages of the disease.

PMID: 21082984